Newtown, Pennsylvania (PRWEB) January 16, 2013
Prestium Pharma today announced the commercial launch of Elimite™ Cream (Permethrin) 5%, indicated for the treatment of scabies. “We are excited to have an opportunity to bring a brand like Elimite™ back to the market” stated John Denman, General Manager of Prestium Pharma. “The incidence rate of scabies in the United States unfortunately continues to grow at a rapid pace, and the active ingredient in Elimite™ is the most widely prescribed treatment option. This product is an important addition to the growing Prestium Pharma portfolio.”
Elimite™ Cream (Permethrin) 5% is a prescription medication for the treatment of scabies, a health condition caused by an infestation of human itch mites. Scabies is spread very easily from person to person through simple physical contact. A person who has scabies can transmit the mites to their family members, friends, coworkers and others by shaking hands or otherwise coming in contact with exposed skin. Additional information about both Elimite™ and scabies can be found at http://www.ElimiteRX.com.
About Prestium: Prestium Pharma, a subsidiary of Renaissance Acquisition Holdings, focuses on acquiring, licensing and selling in-market branded prescription products, including mature brands with or without generic competition. More information about Prestium can be found at http://www.PrestiumPharma.com.